Some people taking GLP-1 medications describe a change that goes beyond eating less. Food occupies their thoughts less often, and they may notice less interest in activities they previously enjoyed. <\/p>\n
They may not feel sad or depressed<\/a>, but describe themselves as emotionally flat or indifferent.<\/p>\n This experience has been called the \u201cOzempic personality<\/a>\u201d or the \u201cmeh effect,\u201d although neither term is a medical diagnosis. Because GLP-1 medications affect brain systems involved in reward and motivation<\/a> as well as appetite<\/a>, some researchers and clinicians have considered whether these reports could involve anhedonia<\/a>, a diminished capacity to experience pleasure. That possibility is still far from established, particularly because the changes reported by patients vary considerably.<\/p>\n The Brain\u2019s Reward System<\/p>\n GLP-1 receptor agonists such as semaglutide are primarily discussed in terms of appetite, digestion, and blood glucose. But GLP-1 signaling also interacts with neural<\/a> circuits involved in reward. <\/p>\n Research suggests that these medications change the brain\u2019s response to food-related cues, particularly highly palatable foods. A 2024 systematic review found consistent effects on reward-related behavior, although their precise mechanisms remain unclear.<\/p>\n To understand how GLP-1 medications may affect reward, it helps to distinguish between wanting and liking. Wanting is the motivational drive to seek a reward, while liking refers to the pleasure experienced when the reward is obtained. <\/p>\n This distinction is relevant because reducing food-related wanting can be therapeutic when cravings contribute to overeating. It becomes more complicated when changes in motivation are no longer specific to food, particularly if activities that were previously rewarding also become less appealing.<\/p>\n The Effect Is Not Just Psychological<\/p>\n The effects of GLP-1 medications on reward are not simply psychological reactions to eating less or losing weight. GLP-1 receptors are found in brain regions involved in motivation and reward, and GLP-1 signaling can affect neural pathways that regulate dopamine<\/a> and other processes involved in how rewards are valued.<\/p>\n This provides a biological basis for some of the changes people describe after starting semaglutide. The medication can alter how the brain processes the motivational value of food, rather than simply making a person decide to eat less.<\/p>\n What remains uncertain is whether these effects can extend beyond food to produce broader changes in motivation or pleasure.<\/p>\n Other Possible Causes of Anhedonia Should Be Considered<\/p>\n Anhedonia can have several possible causes, including other medications, substance use, sleep disturbances, neurological conditions, and changes in physical health. These factors can affect the brain\u2019s reward and motivation systems independently of GLP-1 treatment.<\/p>\n This becomes important when anhedonia appears after starting semaglutide. A symptom that begins during treatment may be related to the medication, but it may also have another cause that emerged around the same time.<\/p>\n The timing alone therefore cannot establish that semaglutide is responsible.<\/p>\n GLP-1s Often Improve Mental Health<\/p>\n Despite reports of emotional flattening or reduced interest among some people taking GLP-1 medications, clinical studies have generally found improvements in mental health during treatment.<\/p>\n A 2025 systematic review and meta-analysis<\/a> of 80 randomized clinical trials involving more than 107,000 participants found that GLP-1 receptor agonists were associated with better mental health-related quality of life, without an increased risk of psychiatric<\/a> adverse events.<\/p>\n This does not make individual reports of anhedonia less real. It does, however, place them in the context of what has been observed across much larger groups of patients. A person may experience a reduction in pleasure or motivation while the average participant in a clinical trial experiences an improvement in psychological well-being.<\/p>\n The two findings are therefore not necessarily contradictory, since clinical trials describe what tends to happen across a population, while individual reports can reveal effects that are less common or that are not captured by the measures used in those trials.<\/p>\n","protected":false},"excerpt":{"rendered":"Some people taking GLP-1 medications describe a change that goes beyond eating less. Food occupies their thoughts less…\n","protected":false},"author":2,"featured_media":1188813,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[3,4],"tags":[748,393,4884,1144,712,16,15,1764],"class_list":["post-1188812","post","type-post","status-publish","format-standard","has-post-thumbnail","category-uk","category-united-kingdom","tag-britain","tag-england","tag-great-britain","tag-northern-ireland","tag-scotland","tag-uk","tag-united-kingdom","tag-wales"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/117221500062717996","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1188812","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=1188812"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/1188812\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/1188813"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=1188812"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=1188812"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=1188812"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}